According to new research published in the journal PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Cell Biology at the University of Colorado School of Medicine in Denver, Colorado, and Taiga Biotechnologies, Inc. have discovered a new method to increase the production of stem cells used to treat patients with cancer undergoing bone marrow transplants. The team of researchers designed proteins that can be directly administered to blood stem cells to increase multiplication.
Dennis Roop, PhD, director of the Gates Stem Cell Center, says that researchers have long tried to increase the number of stem cells in vitro with minimal success, until now. Researchers have successfully studied this new method with blood stem cells from cord blood, adult bone marrow, and adult peripheral blood.
The researchers hope to start human clinical trials soon to test the new method. Taiga Biotechnologies, Inc. is already in the process of doing just that, and hope to study the method in patients with leukemia, lymphoma, myeloma, and certain solid tumors, as well as patients with autoimmune diseases, inborn immunodeficiency, and metabolic conditions.
A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.